Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC

Zentalis Pharmaceuticals, Inc.

RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.
Confirmed ORR 36.8% (7/19) in ovarian/USC with intermittent dosing vs 19.2% (5/26) continuous.
No discontinuations due to TRAEs in intermittent cohorts; improved tolerability over continuous dosing.
Three Phase 2 monotherapy trials enrolling: Cyclin E1+ ovarian, USC, PARPi-resistant ovarian cancer.
Company plans H2 2023 update on Phase 1 dose optimization data and Phase 2 program timelines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.